We are looking for people living with type 1 diabetes who have ongoing low blood sugar, particularly at night, but have otherwise stable diabetes management. Participants should not have frequent severe hypoglycemia or recent visits to the hospital because of diabetes problems. This study will explore if a new medication, only available in a research study, can reduce nighttime low blood sugar events. One of three drug doses will be compared to a placebo for each research participant to see if blood sugars are better managed overnight and throughout the day. Total time in study is approximately 18 weeks (4.5 months). Study visits are conducted in the mornings at the Clinical Trials Unit at Richmond Road Diagnostic and Treatment Centre.

The goal of this study is to better understand the experience of patients and their caregivers during the period surrounding the onset of dialysis. We will also assess changes in quality of life and physical vulnerability (frailty) of patients before dialysis initiation and up to 1 year after dialysis initiation. We will also assess the burden on caregivers. We want to compare groups that start with home dialysis and with hemodialysis in the center.

The complement system is made up of different proteins in the blood, and is part of the body’s immune system. Complement is part of the body’s defense against infection, but complement can also cause injury to our body’s own tissues. We are studying whether problems in the complement system may explain the pregnancy complications and blood clots that happen to pregnant patients with antiphospholipid syndrome (APS), a serious blood clotting condition. To help answer this question, we are looking for pregnant women who have APS and pregnant women who do not have APS. We would like to get blood work regularly during pregnancy including in people who do not have APS, which will test complement, blood clotting and platelet markers. We are also looking for people who are not pregnant and do not have APS, to give blood up to 3 times to test complement, blood clotting and platelet markers.

This study is being done to better understand how well the medication mepolizumab (NUCALA) is working in routine medical practice to treat a sub-population of adult patients with severe asthma who have what is termed an eosinophilic phenotype (SA-EP). Mepolizumab is approved (marketed drug) in Canada. Study participants will be asked to complete questionnaires and lung function testing in addition to their standard of care visit. Participation in the study will last 2 years.

The SAVER Trial is a research study (trial) being conducted to determine if a cholesterol-lowering medication (statin) can help prevent blood clots in people with deep vein thrombosis or pulmonary embolism. The purpose of this study is to examine if adding a statin (rosuvastatin) to the usual blood thinner treatment will decrease the risk of another blood clot forming. We also hope to discover if taking a statin reduces damage to your veins. If you are eligible and consent to the trial, then you would be randomly assigned to take either a statin medication or a placebo. You will have follow-up phone calls or visits every 6 months, for a minimum of 6 months, up to a maximum of 5 years. A member of the research team can provide more information about the trial if you are interested in hearing more.

Sponsor is doing this research to find out if an experimental medication, benralizumab, will work and be safe for the treatment of EGPA. To see if benralizumab has an impact in treating EGPA, this study will compare it with an active comparator, mepolizumab, that has regulatory approval in several markets for use in patients with EGPA.

Human rhinovirus is also called the “common cold virus” because it causes at least half of all of the common colds experienced each year. In patients with asthma, getting a rhinovirus infection can cause worsening of asthma symptoms. Although these symptoms are well known, we do not fully understand how the virus worsens these asthma symptoms, nor do we really know whether virus infection causes longer term structural changes (often referred to as airway remodeling) in the airways. This study plans to address and answer these questions. Doing so will provide us with a better understanding of how to treat asthma worsenings that are caused by human rhinovirus infections. The epithelial cell is the cell that lines the surface of your airways from your nose down to your lungs, and is also the cell type that gets infected by rhinovirus. At present, it is thought that the virus causes symptoms by changing epithelial cell biology in a way that causes airway inflammation. Some of these inflammatory molecules are also thought to cause scarring (remodeling) of the airways, which over time, may lead to a loss of lung function. In order to examine how the virus causes inflammation, many earlier studies have used experimental infection with the virus and have measured various markers of inflammation. The purpose of this study is to compare the levels of inflammatory and remodeling products in the airways of study participants with mild to moderate asthma and healthy, non-asthmatic subjects after infection with rhinovirus (the common cold virus).

A clinical research study to evaluating the safety and tolerability of 2 mg once daily vs. 1 mg twice daily budesonide orodispersible tablets in study participants with eosinophilic esophagitis

University of Calgary researchers are looking for people with Type 1 Diabetes who would like to share their experiences exercising or avoiding exercise in one interview lasting up to 90 minutes.

Currently the Biobank of the Molecular Classification of Kidney Disease (BMCKD) is a fully operational biobank operating in both clinical and research capacities. The BMCKD collects, processes, stores, and transfers biospecimens from patients who have evidence or diagnoses of kidney disease. As the BMCKD continues to expand the size of its repository, it becomes increasingly important to collect biospecimens from healthy volunteers in order to provide healthy control groups for comparative analysis to support future research projects in precise diagnostic testing and genetic studies. Participants provide a ONE TIME donation of blood and urine which will be de-identified.